MA58087B1 - Nouveaux dérivés de méthylquinazolinone - Google Patents
Nouveaux dérivés de méthylquinazolinoneInfo
- Publication number
- MA58087B1 MA58087B1 MA58087A MA58087A MA58087B1 MA 58087 B1 MA58087 B1 MA 58087B1 MA 58087 A MA58087 A MA 58087A MA 58087 A MA58087 A MA 58087A MA 58087 B1 MA58087 B1 MA 58087B1
- Authority
- MA
- Morocco
- Prior art keywords
- methylquinazolinone
- derivatives
- new
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Harvester Elements (AREA)
- Combines (AREA)
Abstract
L'invention concerne un nouveau composé ayant la formule générale (I), ou un sel pharmaceutiquement acceptable de celui-ci. Le composé de formule (I) peut être utilisé en tant que médicament.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214941 | 2019-12-10 | ||
| PCT/EP2020/084976 WO2021116055A1 (fr) | 2019-12-10 | 2020-12-08 | Nouveaux dérivés de méthylquinazolinone |
| EP20817377.3A EP4073065B1 (fr) | 2019-12-10 | 2020-12-08 | Nouveaux dérivés de methylquinazolinone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA58087B1 true MA58087B1 (fr) | 2025-04-30 |
Family
ID=68848113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA58087A MA58087B1 (fr) | 2019-12-10 | 2020-12-08 | Nouveaux dérivés de méthylquinazolinone |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12116349B2 (fr) |
| EP (2) | EP4483882A3 (fr) |
| JP (2) | JP7108146B2 (fr) |
| KR (1) | KR102836833B1 (fr) |
| CN (2) | CN114787156B (fr) |
| AR (1) | AR122351A1 (fr) |
| AU (1) | AU2020403443B2 (fr) |
| CL (1) | CL2022001529A1 (fr) |
| CO (1) | CO2022008968A2 (fr) |
| CR (1) | CR20220251A (fr) |
| DK (1) | DK4073065T3 (fr) |
| ES (1) | ES3023264T3 (fr) |
| FI (1) | FI4073065T3 (fr) |
| HR (1) | HRP20250418T1 (fr) |
| HU (1) | HUE071148T2 (fr) |
| IL (2) | IL316473A (fr) |
| LT (1) | LT4073065T (fr) |
| MA (1) | MA58087B1 (fr) |
| MX (1) | MX2022006783A (fr) |
| PE (1) | PE20221778A1 (fr) |
| PH (1) | PH12022551119A1 (fr) |
| PL (1) | PL4073065T3 (fr) |
| PT (1) | PT4073065T (fr) |
| RS (1) | RS66721B1 (fr) |
| SI (1) | SI4073065T1 (fr) |
| TW (2) | TWI877268B (fr) |
| UA (1) | UA128299C2 (fr) |
| WO (1) | WO2021116055A1 (fr) |
| ZA (2) | ZA202204675B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3158541A1 (fr) * | 2019-12-10 | 2021-06-17 | Cosimo Dolente | Nouveaux inhibiteurs de braf en tant que "paradox breakers" |
| SI4073065T1 (sl) | 2019-12-10 | 2025-06-30 | F. Hoffmann-La Roche Ag | Novi derivati metilkinazolinona |
| MX2022015703A (es) | 2020-06-09 | 2023-01-24 | Array Biopharma Inc | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. |
| AU2022290851A1 (en) | 2021-06-08 | 2023-11-23 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| IL308015A (en) * | 2021-06-09 | 2023-12-01 | Hoffmann La Roche | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
| CN117642166A (zh) * | 2021-06-09 | 2024-03-01 | 中外制药株式会社 | 用于癌症治疗的组合疗法 |
| JP2024522603A (ja) * | 2021-06-09 | 2024-06-21 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | (3r)-n-[2-シアノ-4-フルオロ-3-(3-メチル-4-オキソ-キナゾリン-6-イル)オキシ-フェニル]-3-フルオロ-ピロリジン-1-スルホンアミドの新規固形物 |
| EP4378478A4 (fr) | 2021-07-27 | 2025-11-12 | Toray Industries | Médicament pour le traitement et/ou la prévention du cancer |
| IL312171A (en) | 2021-11-04 | 2024-06-01 | Hoffmann La Roche | Innovative use of the quinazolinone compound for cancer treatment |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| JP2025537786A (ja) | 2022-11-18 | 2025-11-20 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 進行性固形がんまたは転移の治療のためのbraf阻害剤としてのキナゾリノン化合物 |
| EP4634171A1 (fr) * | 2022-12-15 | 2025-10-22 | F. Hoffmann-La Roche AG | Procédé de préparation d'un dérivé de quinazolinone |
| JP2025541200A (ja) * | 2022-12-15 | 2025-12-18 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | がん処置のための併用療法 |
| IL324898A (en) | 2023-07-04 | 2026-01-01 | Hoffmann La Roche | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinozolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide |
| WO2025108405A1 (fr) | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | Préparation d'un dérivé de quinazolinone destiné à être utilisé en tant qu'inhibiteur de kinase, et son utilisation |
| WO2025153057A1 (fr) | 2024-01-17 | 2025-07-24 | 海思科医药集团股份有限公司 | Composition pharmaceutique comprenant un inhibiteur de braf et utilisation d'une composition pharmaceutique en médecine |
| WO2026037755A1 (fr) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | Nouveaux dérivés de méthylquinazolinone |
| WO2026046946A1 (fr) | 2024-08-28 | 2026-03-05 | F. Hoffmann-La Roche Ag | Nouvelles formes solides de (3r)-n-[2-cyano-4-fluoro-3-(3-méthyl-4-oxo-quinazolin-6-yl)oxy-phényl]-3-fluoro-pyrrolidine-1-sulfonamide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4429085B2 (ja) | 2004-06-08 | 2010-03-10 | 有限会社コンペックス | 茸栽培用殺菌菌床組成物の製造法及び茸栽培法 |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン,インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| AU2009226136B2 (en) | 2008-03-17 | 2013-08-15 | Ambit Biosciences Corporation | Quinazoline derivatives as RAF kinase modulators and methods of use thereof |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2012118492A1 (fr) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Sulfonamides hétérocycliques en tant qu'inhibiteurs de raf |
| AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| CA2882410A1 (fr) | 2012-09-19 | 2014-03-27 | Novartis Ag | Dihydropyrrolidinopyrimidines comme inhibiteurs de kinase |
| RU2015149937A (ru) | 2013-05-30 | 2017-07-06 | Плексксикон Инк. | Соединения для модулирования киназы и показания к их применению |
| BR112017025045A2 (pt) | 2015-05-22 | 2018-08-07 | Plexxikon Inc | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 |
| PL3359541T3 (pl) | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
| RU2687107C1 (ru) | 2018-06-18 | 2019-05-07 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид |
| WO2020142612A1 (fr) | 2019-01-03 | 2020-07-09 | Genentech, Inc. | Composés de pyrido-pyrimidinone et de ptéridinone utilisés en tant qu'inhibiteurs de l'enzyme nécessitant l'inositol i (ire i alpha) à activité endoribonucléase pour le traitement de maladies cancéreuses |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療braf相關的疾病和失調症之化合物 |
| SI4073065T1 (sl) | 2019-12-10 | 2025-06-30 | F. Hoffmann-La Roche Ag | Novi derivati metilkinazolinona |
| CA3158541A1 (fr) * | 2019-12-10 | 2021-06-17 | Cosimo Dolente | Nouveaux inhibiteurs de braf en tant que "paradox breakers" |
| MX2022015703A (es) | 2020-06-09 | 2023-01-24 | Array Biopharma Inc | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. |
| WO2022129259A1 (fr) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | Nouveaux dérivés de quinazolinone |
| CN118561841A (zh) | 2020-12-18 | 2024-08-30 | 豪夫迈·罗氏有限公司 | 新的芳基-吡啶并-嘧啶-酮衍生物 |
| AU2022290851A1 (en) | 2021-06-08 | 2023-11-23 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| KR20240115893A (ko) | 2021-12-08 | 2024-07-26 | 어레이 바이오파마 인크. | N-(2-클로로-3-((5-클로로-3-메틸-4-옥소-3,4-다이하이드로퀴나졸린-6-일)아미노)-4-플루오로페닐)-3-플루오로아제티딘-1-설폰아미드의결정질 형태 |
-
2020
- 2020-12-08 SI SI202030605T patent/SI4073065T1/sl unknown
- 2020-12-08 AU AU2020403443A patent/AU2020403443B2/en active Active
- 2020-12-08 ES ES20817377T patent/ES3023264T3/es active Active
- 2020-12-08 EP EP24205932.7A patent/EP4483882A3/fr active Pending
- 2020-12-08 IL IL316473A patent/IL316473A/en unknown
- 2020-12-08 PH PH1/2022/551119A patent/PH12022551119A1/en unknown
- 2020-12-08 CN CN202080084994.3A patent/CN114787156B/zh active Active
- 2020-12-08 MX MX2022006783A patent/MX2022006783A/es unknown
- 2020-12-08 WO PCT/EP2020/084976 patent/WO2021116055A1/fr not_active Ceased
- 2020-12-08 LT LTEPPCT/EP2020/084976T patent/LT4073065T/lt unknown
- 2020-12-08 PE PE2022000853A patent/PE20221778A1/es unknown
- 2020-12-08 PT PT208173773T patent/PT4073065T/pt unknown
- 2020-12-08 CN CN202410878222.7A patent/CN118791472A/zh active Pending
- 2020-12-08 DK DK20817377.3T patent/DK4073065T3/da active
- 2020-12-08 RS RS20250354A patent/RS66721B1/sr unknown
- 2020-12-08 CR CR20220251A patent/CR20220251A/es unknown
- 2020-12-08 KR KR1020227023074A patent/KR102836833B1/ko active Active
- 2020-12-08 HR HRP20250418TT patent/HRP20250418T1/hr unknown
- 2020-12-08 IL IL292161A patent/IL292161B2/en unknown
- 2020-12-08 MA MA58087A patent/MA58087B1/fr unknown
- 2020-12-08 JP JP2021566023A patent/JP7108146B2/ja active Active
- 2020-12-08 FI FIEP20817377.3T patent/FI4073065T3/fi active
- 2020-12-08 EP EP20817377.3A patent/EP4073065B1/fr active Active
- 2020-12-08 PL PL20817377.3T patent/PL4073065T3/pl unknown
- 2020-12-08 UA UAA202202163A patent/UA128299C2/uk unknown
- 2020-12-08 HU HUE20817377A patent/HUE071148T2/hu unknown
- 2020-12-09 TW TW109143500A patent/TWI877268B/zh active
- 2020-12-09 AR ARP200103417A patent/AR122351A1/es unknown
- 2020-12-09 TW TW113139852A patent/TWI908405B/zh active
-
2021
- 2021-12-14 JP JP2021202780A patent/JP7802514B2/ja active Active
-
2022
- 2022-04-26 ZA ZA2022/04675A patent/ZA202204675B/en unknown
- 2022-06-08 US US17/835,245 patent/US12116349B2/en active Active
- 2022-06-09 CL CL2022001529A patent/CL2022001529A1/es unknown
- 2022-06-22 ZA ZA2022/06923A patent/ZA202206923B/en unknown
- 2022-06-28 CO CONC2022/0008968A patent/CO2022008968A2/es unknown
-
2023
- 2023-11-30 US US18/525,536 patent/US20240174621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52948B1 (fr) | Composés | |
| MA46337A (fr) | Composé de pyridine | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| CR20200588A (es) | Compuestos novedosos | |
| EA201892300A1 (ru) | Макроциклические ингибиторы mcl1 для лечения рака | |
| MA51431B1 (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MA38472A1 (fr) | Composé peptidique | |
| MA45782B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA46101B1 (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA41338A (fr) | Composés de pyrazine pour le traitement de maladies infectieuses | |
| MA38390B1 (fr) | Composés tétrahydropyrrolothiazines | |
| MA42341B2 (fr) | Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale | |
| MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
| MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| MA39983A (fr) | Dérivés de carboxamide | |
| JOP20210039B1 (ar) | مركبات بيريدين 6،2 - ديامينو | |
| MA38865A1 (fr) | Formulation comprenant un agent hypolipidémiant | |
| MX2020004930A (es) | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| SA522441650B1 (ar) | مثبطات فوسفوينوسيتيد 3-كيناز الموضعية | |
| MA46039B1 (fr) | Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain |